Total Payments
$141,453
2024 Payments
$1,876
Companies
12
Transactions
138
Medicare Patients
1,373
Medicare Billing
$791,470
Payment Breakdown by Category
Other$50,185 (35.5%)
Consulting$43,996 (31.1%)
Research$38,036 (26.9%)
Travel$7,712 (5.5%)
Food & Beverage$1,524 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50,185 | 22 | 35.5% |
| Consulting Fee | $43,996 | 21 | 31.1% |
| Unspecified | $38,036 | 42 | 26.9% |
| Travel and Lodging | $7,712 | 28 | 5.5% |
| Food and Beverage | $1,524 | 25 | 1.1% |
Payments by Type
General
$103,417
96 transactions
Research
$38,036
42 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $38,745 | 35 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $25,368 | 21 | $0 (2023) |
| Celgene Corporation | $22,010 | 11 | $0 (2021) |
| Astellas Pharma Global Development | $18,591 | 28 | $0 (2022) |
| PFIZER INC. | $16,101 | 13 | $0 (2019) |
| ABBVIE INC. | $10,698 | 18 | $0 (2024) |
| F. Hoffmann-La Roche AG | $4,557 | 1 | $0 (2023) |
| JAZZ PHARMACEUTICALS INC. | $4,216 | 6 | $0 (2019) |
| Acceleron Pharma, Inc. | $845.00 | 1 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $174.59 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,876 | 2 | Incyte Corporation ($1,370) |
| 2023 | $10,546 | 7 | F. Hoffmann-La Roche AG ($4,557) |
| 2022 | $3,202 | 4 | Novartis Pharmaceuticals Corporation ($2,700) |
| 2021 | $15,210 | 10 | Celgene Corporation ($9,900) |
| 2020 | $14,909 | 17 | Astellas Pharma Global Development ($6,979) |
| 2019 | $27,719 | 47 | Astellas Pharma Global Development ($10,786) |
| 2018 | $32,800 | 28 | Incyte Corporation ($17,881) |
| 2017 | $35,191 | 23 | NOVARTIS PHARMACEUTICALS CORPORATION ($11,958) |
All Payment Transactions
138 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 03/11/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $506.25 | General |
| 12/11/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $77.09 | General |
| Category: Hematology/Oncology | ||||||
| 12/09/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $48.51 | General |
| Category: Hematology/Oncology | ||||||
| 12/07/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $3,037.50 | General |
| 12/07/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Food and Beverage | In-kind items and services | $185.89 | General |
| 08/16/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $4,557.24 | Research |
| Study: Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: Stage 1 of a Phase II trial | ||||||
| 05/09/2023 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $615.00 | General |
| 10/18/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 09/07/2022 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 08/10/2022 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.50 | General |
| Category: Hematology/Oncology | ||||||
| 07/15/2022 | Astellas Pharma Global Development | Xospata (Drug) | — | In-kind items and services | $358.00 | Research |
| Study: CL-301 PRO From the Phase 3 ADMIRAL Trial in Patients • Category: Oncology | ||||||
| 11/08/2021 | Incyte Corporation | PEMAZYRE (Drug) | Consulting Fee | Cash or cash equivalent | $1,845.00 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 10/27/2021 | Incyte Corporation | JAKAFI (Drug) | Consulting Fee | Cash or cash equivalent | $2,152.50 | General |
| Category: Hematology/Oncology | ||||||
| 09/27/2021 | Celgene Corporation | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Hematology | ||||||
| 07/28/2021 | Celgene Corporation | REBLOZYL (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,310.00 | General |
| Category: Hematology | ||||||
| 07/28/2021 | Celgene Corporation | REBLOZYL (Biological) | Travel and Lodging | Cash or cash equivalent | $814.56 | General |
| Category: Hematology | ||||||
| 07/28/2021 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Hematology | ||||||
| 07/26/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $358.13 | Research |
| Study: A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. • Category: ONCOLOGY | ||||||
| 04/07/2021 | Acceleron Pharma, Inc. | Reblozyl (Drug) | Consulting Fee | Cash or cash equivalent | $845.00 | General |
| Category: Hematology | ||||||
| 03/11/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $110.00 | Research |
| Study: A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. • Category: ONCOLOGY | ||||||
| 01/26/2021 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 12/16/2020 | Novartis Pharmaceuticals Corporation | ABL002 (Drug) | Consulting Fee | Cash or cash equivalent | $2,620.00 | General |
| 11/16/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $1,128.57 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation | Astellas Pharma Global Development | $10,726 | 11 |
| OUTCOMES RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $8,759 | 4 |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | Astellas Pharma Global Development | $6,979 | 13 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $6,129 | 9 |
| Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: Stage 1 of a Phase II trial | F. Hoffmann-La Roche AG | $4,557 | 1 |
| A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. | Astellas Pharma Global Development | $468.13 | 2 |
| CL-301 PRO From the Phase 3 ADMIRAL Trial in Patients | Astellas Pharma Global Development | $358.00 | 1 |
| A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation | Astellas Pharma Global Development | $60.01 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 223 | 916 | $381,250 | $78,922 |
| 2022 | 5 | 243 | 816 | $270,050 | $76,115 |
| 2021 | 8 | 463 | 40,262 | $866,470 | $287,109 |
| 2020 | 10 | 444 | 51,355 | $1.0M | $349,323 |
Total Patients
1,373
Total Services
93,349
Medicare Billing
$791,470
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 154 | 778 | $330,650 | $65,781 | 19.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 76 | $26,600 | $8,248 | 31.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 24 | 24 | $12,600 | $2,907 | 23.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 26 | 38 | $11,400 | $1,987 | 17.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 149 | 586 | $211,990 | $48,356 | 22.8% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 36 | 109 | $17,440 | $17,395 | 99.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 28 | 83 | $27,850 | $7,642 | 27.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $6,300 | $1,375 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 18 | 26 | $6,470 | $1,348 | 20.8% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2021 | 19 | 38,600 | $386,000 | $103,190 | 26.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 127 | 593 | $201,620 | $68,056 | 33.8% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 59 | 326 | $52,160 | $52,470 | 100.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 59 | 309 | $101,970 | $29,388 | 28.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 94 | 232 | $78,880 | $21,704 | 27.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 40 | 61 | $14,030 | $4,497 | 32.1% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Office | 2021 | 14 | 17 | $10,200 | $2,958 | 29.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 18 | 18 | $9,450 | $2,815 | 29.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 21 | 94 | $9,400 | $1,270 | 13.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 12 | 12 | $2,760 | $761.64 | 27.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2020 | 19 | 49,400 | $494,000 | $147,603 | 29.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 130 | 1,010 | $343,400 | $100,541 | 29.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 64 | 399 | $63,840 | $63,648 | 99.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 59 | 208 | $68,640 | $20,000 | 29.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 55 | 102 | $23,460 | $7,209 | 30.7% |
| 38222 | Bone marrow biopsy and aspiration | Office | 2020 | 17 | 30 | $18,000 | $5,055 | 28.1% |
About Dr. Ellen Ritchie, MD
Dr. Ellen Ritchie, MD is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003996653.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ellen Ritchie, MD has received a total of $141,453 in payments from pharmaceutical and medical device companies, with $1,876 received in 2024. These payments were reported across 138 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($50,185).
As a Medicare-enrolled provider, Ritchie has provided services to 1,373 Medicare beneficiaries, totaling 93,349 services with total Medicare billing of $791,470. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology, Medical Oncology
- Location New York, NY
- Active Since 10/17/2006
- Last Updated 09/16/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1003996653
Products in Payments
- JAKAFI (Drug) $21,097
- XOSPATA (Drug) $18,233
- TASIGNA (Drug) $14,977
- REBLOZYL (Biological) $6,900
- DAURISMO (Drug) $6,780
- Venclexta (Drug) $5,664
- VYXEOS (Drug) $4,216
- ABL002 (Drug) $3,157
- PEMAZYRE (Drug) $1,845
- Luspatercept (Drug) $1,500
- BOSULIF (Drug) $1,250
- Reblozyl (Drug) $845.00
- MYLOTARG (Biological) $512.62
- Xospata (Drug) $358.00
- KANJINTI (Biological) $22.34
- Idhifa (Drug) $15.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M